Due to the pulsatile swelling on the left anterior chest wall, computed tomography angiography (CTA) imaging was performed immediately. It revealed that the pseudoaneurysm, measuring 77.8?62.9?58.6 mm, was located at the ascending aorta, corresponding to the aortic cannulation site ( Figure 1a, 2c). The distance between the neck of the pseudoaneurysm and vital structures such as brachiocephalic artery, proximal anastomoses of the RCA and OM1 was safe for ASD closure device on CTA. Transthoracic echocardiography (TTE) showed an APA with an ellipsoid-shaped neck measuring 25.8?37 mm, filling with contrast material during each cardiac cycle and located between the ascending aorta and the pseudoaneurysm sac ( Figure 1b). Systolic left ventricle functions were normal (left ventricle ejection fraction: 60%). The structure of aortic valve was determined normal and there was mild mitral regurgitation. Coronary angiography revealed that SVG to RCA and LIMA graft were patent, and SVG to CxOM1 was occluded. After the patient was evaluated by the Heart Team, the surgical procedure was deemed high risk and it was decided to perform the intervention using an ASD closure device.
The procedure was performed under the guidance of conventional angiography and TTE. A pigtail catheter was placed over a 0.035-inch guidewire into the ascending aorta through right radial artery access. Judkins right diagnostic catheter and the super stiff guidewire were placed over a 0.035-inch guidewire into the pseudoaneurysm sac through right femoral artery access. The delivery system was, then, placed to the aneurysm sac under the guidance of fluoroscopy and TTE. Since the APA neck had an ellipsoidal shape and its long axis diameter was 37 mm, the left disc of the 39-mm Occlutech Figulla® F lex I I A SD c losure d evice (OFF II, Occlutech International AB, Helsingborg, Sweden) was positioned inside the pseudoaneurysm sac and the right disc was positioned in the ascending aorta without any complications ( Figure 1c). At the end of the procedure, the flow in the sac decreased and there was stagnation in the contrast staining sac. The TTE repeated in the days following the procedure showed that the flow toward the pseudoaneurysm decreased progressively, and the sac of the pseudoaneurysm was seen to be completely thrombosed at the end of the first postoperative week. After the patient's hemodynamic status stabilized, he was discharged with antiplatelet therapy. No complications developed during follow-up and his complaints were completely resolved. During follow-up one month after the procedure, TTE confirmed no flow into the sac of the pseudoaneurysm and CT scan showed that the sac of the pseudoaneurysm is completely trombosed ( Figure 2a, 2b, 2d). Written informed consent was obtained from the patient.
The size, shape and neck of the pseudoaneurysm sac and the possible interaction of the device to be used with adjacent anatomical structures are the technical determinants for the success of the procedure. The ASD closure device should be large enough to completely cover the neck of the pseudoaneurysm and should not damage adjacent anatomical structures, when the device is precisely positioned. Therefore, the distance of the pseudoaneurysm to the coronary ostia, aortic leaflets and aortic arch elements is of paramount importance.[7] Various imaging tools such as CTA imaging, TTE and/or transesophageal echocardiography, and cardiac magnetic resonance imaging can be used to accurately evaluate all of these structures.[4] In patients with a very high risk of rupture, as in our case, percutaneous closure of the pseudoaneurysm, reducing intra-sac pressure and allowing it to thrombose gradually within a week may eliminate the risk of early rupture. However, approximately 20% of these percutaneous closures may cause sac enlargement due to slight leakage into the sac and migration due to malposition of the device. Migration and embolization of the device may occur even after one year of follow-up after the procedure.[1] A lthough t he t iming of follow-up C TA scans in the management of APA is not standardized, it is clear that these patients require a certain level of surveillance. Based on this finding, we would continue to follow our case with CTA imaging for long-term results.
In conclusion, in appropriate cases of aortic pseudoaneurysms where surgical repair poses a high risk, percutaneous repair using an atrial septal defect closure device can be considered as a treatment option which can prevent the high risk. However, for the safety and effectiveness of this technique, analysis of data on similar case reports from more than one center regarding percutaneous closure is needed.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Author Contributions: All authors contributed equally to the article.
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Funding: The authors received no financial support for the research and/or authorship of this article.
1) Patel AV, Gupta S, Laffin LJ, Retzer EM, Dill KE,
Shah AP. One size does not fit all: Case report of two
percutaneous closures of aortic pseudoaneurysm and review
of the literature. Cardiovasc Revasc Med 2014;15:160-4. doi: 10.1016/j.carrev.2014.02.007.
2) Quevedo HC, Santiago-Trinidad R, Castellanos J, Atianzar
K, Anwar A, Abi Rafeh N. Systematic review of interventions
to repair ascending aortic pseudoaneurysms. Ochsner J
2014;14:576-85.
3) Wu Y, Fan L, Liu F, Zhuang H, Wu X. Minimally invasive
closure of a progressive pseudoaneurysm of the ascending
aorta: A case report. Front Cardiovasc Med 2023;10:1134196.
doi: 10.3389/fcvm.2023.1134196.
4) Akgül A, Bahar İ, Babaroğlu S, Çobanoğlu A. Aortic
pseudoaneurysm formation following multiple valve
replacement. Turk Gogus Kalp Dama 2009;17:293-5
5) Carmans L, De Meester P, Budts W, Troost E. Percutaneous
closure of an uncommon aortic pseudoaneurysm after arterial
switch repair: A case report. Eur Heart J Case Rep 2019;3:1-4. doi: 10.1093/ehjcr/ytz178.